Evidence map›Paper›PMID 39227240›Full record

ReviewTrends in biotechnology2025

Engineering therapeutical extracellular vesicles for clinical translation.

Yifan Ma, Shiyan Dong, Adam J Grippin, Lesheng Teng, Andrew S Lee, Betty Y S Kim, Wen Jiang

Abstract readReview
In one paragraph

Review in Trends in biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Endogenous Engineering Reprograms Extracellular Vesicles for Enhanced Therapeutic Function.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yifan MaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shiyan DongDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adam J GrippinDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lesheng TengSchool of Life Sciences, Jilin University, Changchun, China.
Andrew S LeePeking University Shenzhen Graduate School, Shenzhen, China; Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Betty Y S KimDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: bykim@mdanderson.org.
Wen JiangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: wjiang4@mdanderson.org.

Funding

Interdisciplinary Translational Pre/Postdoctoral Program in Cancer NanotechnologyT32CA196561 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Gang Bao, Konstantin V Sokolov · 2015 to 2026
$3.0M
Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer ImmunotherapyR01CA284108 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JIANG, WEN, KIM, BETTY · 2023 to 2025
$2.2M
Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastomaR01CA291876 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Wen Jiang, Betty Kim · 2024 to 2026
$1.9M
NCI NIH HHS R01 CA284108NCI NIH HHS R01 CA291876NCI NIH HHS T32 CA196561
6 · The paper itself

Abstract

Cell-based therapies are revolutionizing medicine by replacing or modifying dysfunctional cells with healthy cells or engineered derivatives, offering disease reversal and cure. One promising approach is using cell-derived extracellular vesicles (EVs), which offer therapeutic benefits similar to cell transplants without the biosafety risks. Although EV applications face challenges like limited production, inadequate therapeutic loading, and poor targeting efficiency, recent advances in bioengineering have enhanced their effectiveness. Herein, we summarize technological breakthroughs in EV bioengineering over the past 5 years, highlighting their improved therapeutic functionalities and potential clinical prospects. We also discuss biomanufacturing processes, regulation, and safety considerations for bioengineered EV therapies, emphasizing the significance of establishing robust frameworks to ensure translation capability, safety, and therapeutic effectiveness for successful clinical adoption.

Indexed as

Extracellular VesiclesAnimalsBioengineeringCell- and Tissue-Based TherapyHumansTranslational Research, Biomedicalbioengineeringbiomanufacturingclinical applicationextracellular vesiclestherapeutics

Identifiers

PMID39227240
PMCPMC11717644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.